We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Transfused RBCs Rapidly Recover From Metabolic Storage Lesions

By LabMedica International staff writers
Posted on 20 Jul 2022
Print article
Image: Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion (Photo courtesy of openPR)
Image: Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion (Photo courtesy of openPR)

Directly after red blood cell (RBC) transfusion, a significant number of RBCs are cleared from the circulation; in some patients, up to 38% of the transfused RBCs are cleared in the first 24 hours.

During storage, RBCs undergo several metabolic and morphological changes, known as the “storage lesion.” The metabolic changes include decreased cellular levels of 2,3-diphosphoglycerate (2,3-DPG), adenosine triphosphate (ATP), and impaired redox metabolism. Decrease in the intracellular pH contributes significantly to the storage lesion.

Hematologists at the University of Amsterdam (Amsterdam, The Netherlands) conducted an open-label randomized controlled trial to study the effect of storage time and additive solution on the post-transfusion recovery (PTR) of RBCs. Twenty healthy male subjects were recruited who donated 500 mL and 200 mL of whole blood in citrate-phosphate-dextrose (CPD) at the national blood bank 35 and two days before the transfusion, respectively.

In this trial the effect of storage, phosphate-adenine-glucose-guanosine-gluconate-mannitol (PAGGGM) versus saline-adenine-glucose-mannitol (SAGM), on post-transfusion recovery (PTR) and metabolic restoration after transfusion was assessed. Subjects received an autologous biotinylated RBC concentrate stored for 35 days in SAGM or PAGGGM. As a reference for the PTR, a 2-day stored autologous biotinylated RBC concentrate stored in SAGM was simultaneously transfused. RBC phenotype and PTR were assessed after transfusion.

EDTA anti-coagulated blood samples were analyzed one day after sampling. The amount of bioRBCs was quantified by flow cytometry after staining with Streptavidin Alexa Fluor 647 conjugate. All flow cytometry experiments were performed with a flow cytometer: BD FACS, BD Fortessa + High Throughput Sampler (HTS), (BD Biosciences, San Jose, CA, USA). BioRBCs were isolated in two separate steps from the EDTA whole blood samples. This procedure was based on the differences in biotin density. In the first step, bioRBCs were isolated using magnetic beads, followed by the second step using flow cytometric cell sorting. Ultra-high pressure liquid chromatography–mass spectrometry analyses were performed using a Vanquish UHPLC coupled online to a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany).

The investigators reported that the PTR was significantly higher in the 2-day stored RBCs than in 35-day stored RBCs two and seven days after transfusion: 96% (range 90% to 99%) versus 72% (66% to 89%) and 96% (90% to 99%) versus 72% (66% to 89%), respectively. PTR of SAGM- and PAGGGM-stored RBCs did not differ significantly. Glucose and redox metabolism were better preserved in PAGGGM-stored RBCs. The differences measured in the blood bag remained present only until one day after transfusion. No differences in RBC phenotype were found besides an increased complement C3 deposition on 35-day RBCs stored in PAGGGM.

The authors concluded that despite a better metabolic profile of PAGGGM RBCs, PAGGGM storage did not lead to a higher PTR. Therefore, storage PAGGGM is not a superior alternative for storage in SAGM. Furthermore, the metabolic storage lesion was corrected within a day after transfusion. Finally, 35 days of storage resulted in a lower PTR compared with two days of storage. The study was published on July 6, 2022 in the journal Blood Advances.

Related Links:
University of Amsterdam 
BD Biosciences 
Thermo Fisher 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.